Sickle cell gene therapy breakthrough (commercially available)
Key Questions
What is the status of CASGEVY in sickle cell disease?
CASGEVY is commercially available and provides pain and transfusion-free outcomes for sickle cell patients. Long-term access and equity remain priorities.
What results did the RUBY trial show for reni-cel?
RUBY trial with reni-cel using CRISPR Cas12a achieved 27/28 patients crisis-free in sickle cell disease. This represents a gene therapy breakthrough.
Are there other gene editing advances for hemoglobinopathies?
Base editing shows early promise for beta thalassemia. Gene editing therapies demonstrate potential for severe sickle cell, with one-time treatments reducing symptoms.
CASGEVY commercial pain/transfusion-free; RUBY reni-cel CRISPR Cas12a 27/28 crisis-free; pig hearts HF. Long-term/access/equity.
Sources (2)
Updated Apr 8, 2026